P

Inventor

THOTA SAMBAIAH

US45 patents
⚠️ This page may combine multiple inventors who share the name “THOTA SAMBAIAH”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

RIGEL PHARMACEUTICALS INC

24 patents
US7858633B2Dec 28, 2010

Cycloalkyl substituted pyrimidinediamine compounds and their uses

RIGEL PHARMACEUTICALS INC66 citations98
US7947698B2May 24, 2011

Compositions and methods for inhibition of the JAK pathway

RIGEL PHARMACEUTICALS INC55 citations97
US7834024B2Nov 16, 2010

Compositions and methods for inhibition of the JAK pathway

RIGEL PHARMACEUTICALS INC59 citations97
US7754714B2Jul 13, 2010

Cycloalkyl substituted pyrimidinediamine compounds and their uses

RIGEL PHARMACEUTICALS INC39 citations95
US7915273B2Mar 29, 2011

Compositions and methods for inhibition of the JAK pathway

RIGEL PHARMACEUTICALS INC33 citations93
US7868013B2Jan 11, 2011

Cycloalkyl substituted pyrimidinediamine compounds and their uses

RIGEL PHARMACEUTICALS INC25 citations91
US10421752B2Sep 24, 2019

Compositions and methods for inhibition of the JAK pathway

RIGEL PHARMACEUTICALS INC3 citations84
US9732073B2Aug 15, 2017

Compositions and methods for inhibition of the JAK pathway

RIGEL PHARMACEUTICALS INC4 citations84
US9725419B2Aug 8, 2017

Cycloalkyl substituted pyrimidinediamine compounds and their uses

RIGEL PHARMACEUTICALS INC7 citations84
US9248190B2Feb 2, 2016

Compositions and methods for inhibition of the JAK pathway

RIGEL PHARMACEUTICALS INC4 citations84
US8815848B2Aug 26, 2014

Compositions and methods for inhibition of the JAK pathway

RIGEL PHARMACEUTICALS INC8 citations84
US8012955B2Sep 6, 2011

N-substituted-heterocycloalkyloxybenzamide compounds and methods of use

RIGEL PHARMACEUTICALS INC7 citations84
US11198689B2Dec 14, 2021

Compositions and methods for inhibition of the JAK pathway

RIGEL PHARMACEUTICALS INC2 citations73
US9481654B2Nov 1, 2016

Compositions and methods for inhibition of the JAK pathway

RIGEL PHARMACEUTICALS INC5 citations73
US11827628B2Nov 28, 2023

Compositions and methods for inhibition of the JAK pathway

RIGEL PHARMACEUTICALS INC0 citations63
US11667611B2Jun 6, 2023

Compositions and methods for inhibition of the JAK pathway

RIGEL PHARMACEUTICALS INC0 citations63
US7569580B2Aug 4, 2009

Heterotricyclic compounds for use as HCV inhibitors

RIGEL PHARMACEUTICALS INC6 citations62
US9624229B2Apr 18, 2017

Pyrimidine-2-amine compounds and their use as inhibitors of JAK kinases

RIGEL PHARMACEUTICALS INC0 citations52
US9181220B2Nov 10, 2015

N-substituted-heterocycloalkyloxybenzamide compounds and methods of use

RIGEL PHARMACEUTICALS INC0 citations52
US9174964B2Nov 3, 2015

AMPK-activating piperidinyloxy-substituted 2,3-dihydro-1H-indene-1-amine compounds and pharmaceutical compositions including the same

RIGEL PHARMACEUTICALS INC1 citations52
US9040543B2May 26, 2015

Compositions and methods for inhibition of the JAK pathway

RIGEL PHARMACEUTICALS INC0 citations52
US8895578B2Nov 25, 2014

Carboxamide, sulfonamide and amine compounds and methods for using the same

RIGEL PHARMACEUTICALS INC0 citations52
US9040527B2May 26, 2015

Pyrimidinediamine kinase inhibitors

RIGEL PHARMACEUTICALS INC0 citations51
US7358259B2Apr 15, 2008

HCV inhibitors and methods of using them

RIGEL PHARMACEUTICALS INC0 citations36

LI HUI

8 patents

SINGH RAJINDER

3 patents

HONG HUI

2 patents

DARWISH IHAB S

2 patents

NACUITY PHARMACEUTICALS INC

2 patents

BHAMIDIPATI SOMASEKHAR

1 patent

ATUEGBU ANDY

1 patent

ARGADE ANKUSH

1 patent

COLLABORATIVE MEDICINAL DEV LLC

1 patent